Analysis of Patients who Received Enteral Nutrition in the Course of Chemotherapy
Kawada, J.; Nishino, M.; Hata, T.; Ogino, T.; Hoshino, H.; Okano, M.; Nagai, K.; Kim, Y.; Okuyama, M.; Tsujinaka, T.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 44(10): 900-902
2017
ISSN/ISBN: 0385-0684 PMID: 29066689 Document Number: 693511
Chemotherapy-related adverse events can deteriorate the quality of life, as well as chemotherapy tolerance, for patients with gastric cancer. Nutritional support may prevent chemotherapy-related adverse events. Five patients who received chemotherapy for advanced gastric cancer were prescribed enteral nutrition(Elental®or ENEVO®). We retrospectively evaluated the efficacy and safety of chemotherapy while receiving enteral nutrition. All patients consumed more than one bottle of enteral nutrition during chemotherapy. Median progression-free survival(PFS)and overall survival(OS)were 166 days(100-349)and 328 days(115-431), respectively. Major Grade 3 or 4 adverse events included neutropenia(0%), anemia(40%), and diarrhea(20%). The prognostic nutritional index(PNI)was higher than 40, and the neutrophil lymphocyte ratio(NLR)was lower than 3 over the course of chemotherapy. Nutritional support for gastric cancer patients receiving chemotherapy is feasible. There was a low incidence of chemotherapy-related hematological toxicity, with a relatively longer PFS in patients receiving enteral nutrition.